Gilead Sciences (GILD), Glympse Bio Report Strategic Collaboration for Use of Biomarker Technology in NASH Clinical Development
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
Gilead Sciences (GILD) PT Raised to $90 at RBC Capital
October 28, 2019 6:36 AM EDTRBC Capital analyst Brian Abrahams raised the price target on Gilead Sciences (NASDAQ: GILD) to $90.00 (from $89.00) while maintaining a Top Pick rating.
The analyst commented, "Following publication of our post-earnings report, GILD provided updated information on estimated U.S. HIV patient numbers... More
Intercept Pharma (ICPT) on Watch on Chatter
October 25, 2019 9:36 AM EDTIntercept Pharma (NASDAQ: ICPT) on watch on speculation Gilead Sciences (NASDAQ: GILD) could be eyeing the company per DealReporter.
... MoreGilead Sciences (GILD) PT Lowered to $80 at Oppenheimer
October 25, 2019 8:56 AM EDTOppenheimer analyst Hartaj Singh lowered the price target on Gilead Sciences (NASDAQ: GILD) to $80.00 (from $85.00) while maintaining a Outperform rating.... More
Maxim Group Downgrades Gilead Sciences (GILD) to Hold
October 25, 2019 7:42 AM EDTMaxim Group analyst Jason McCarthy downgraded Gilead Sciences (NASDAQ: GILD) from Buy to Hold.
The analyst comments "We are positive on the outlook for the partnership with Galapagos (GLPG - NR) although that will take time from a revenue perspective, assuming Filgotinib is... More
Gilead Sciences (GILD) PT Lowered to $81 at Raymond James
October 25, 2019 7:30 AM EDTRaymond James analyst Steven Seedhouse lowered the price target on Gilead Sciences (NASDAQ: GILD) to $81.00 (from $85.00) while maintaining a Strong Buy rating.... More
Gilead Sciences (GILD) PT Raised to $86 at Guggenheim
October 25, 2019 7:18 AM EDTGuggenheim analyst Whitney Ljem raised the price target on Gilead Sciences (NASDAQ: GILD) to $86.00 (from $85.00) while maintaining a Buy rating.... More
Gilead Sciences (GILD) PT Lowered to $81 at Wells Fargo
October 25, 2019 6:42 AM EDTWells Fargo lowered its price target on Gilead Sciences (NASDAQ: GILD) to $81.00 (from $89.00) while maintaining a Outperform rating.... More
Gilead Sciences (GILD) PT Lowered to $89 at RBC Capital
October 25, 2019 6:27 AM EDTRBC Capital analyst Brian Abrahams lowered the price target on Gilead Sciences (NASDAQ: GILD) to $89.00 (from $91.00) while maintaining a Top Pick rating.
The analyst commented, "A decent, if relatively uneventful, quarter, with HIV/HCV mixes shifting slightly, Yescarta headwinds emerging, and solid expense... More
Gilead Sciences (GILD) PT Lowered to $81 at BMO Capital
October 25, 2019 5:20 AM EDTBMO Capital analyst Matthew Luchini lowered the price target on Gilead Sciences (NASDAQ: GILD) to $81.00 (from $82.00) while maintaining a Outperform rating.... More
Options expected to have increasing volume: LEA GT ALGT COF GILD FSLR ILMN
October 25, 2019 4:35 AM EDTOptions expected to have increasing volume: LEA GT ALGT COF GILD FSLR ILMN
... MoreGilead Sciences (GILD) Declares $0.63 Quarterly Dividend; 3.8% Yield
October 24, 2019 5:22 PM EDTGilead Sciences (NASDAQ: GILD) declared a quarterly dividend of $0.63 per share, or $2.52 annualized.
The dividend will be payable on December 30, 2019, to stockholders of record on December 13, 2019, with an ex-dividend date of December 12, 2019.
The annual yield on the dividend is 3.8... More
Gilead Sciences (GILD) Tops Q3 EPS by 1c
October 24, 2019 4:03 PM EDTGilead Sciences (NASDAQ: GILD) reported Q3 EPS of $1.75, $0.01 better than the analyst estimate of $1.74. Revenue for the quarter came in at $5.6 billion versus the consensus estimate of $5.61 billion.
GUIDANCE:
Gilead Sciences sees FY2019 revenue of $21.8-22.1 billion, versus the consensus of... More
